Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Patient travel distance and post lung transplant survival in the United States: A cohort study.

Tsuang WM, Arrigain S, Lopez R, Snair M, Budev M, Schold JD.

Transplantation. 2020 Jan 23. doi: 10.1097/TP.0000000000003129. [Epub ahead of print]

PMID:
31985730
2.

The impact of change in definition of increased-risk donors on survival after lung transplant.

Lehr CJ, Lopez R, Arrigain S, Schold J, Koval C, Valapour M.

J Thorac Cardiovasc Surg. 2019 Nov 21. pii: S0022-5223(19)33064-8. doi: 10.1016/j.jtcvs.2019.10.154. [Epub ahead of print]

PMID:
31924361
3.

Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease.

Click B, Lopez R, Arrigain S, Schold J, Regueiro M, Rizk M.

Inflamm Bowel Dis. 2019 Oct 31. pii: izz256. doi: 10.1093/ibd/izz256. [Epub ahead of print]

PMID:
31671186
4.

Characteristics and Outcomes of Patients With Aortic Stenosis and Chronic Kidney Disease.

Patel KK, Shah SY, Arrigain S, Jolly S, Schold JD, Navaneethan SD, Griffin BP, Nally JV, Desai MY.

J Am Heart Assoc. 2019 Feb 5;8(3):e009980. doi: 10.1161/JAHA.118.009980.

5.

What are the Risk Factors for One-Year Mortality in Older Patients with Chronic Kidney Disease? An Analysis of the Cleveland Clinic CKD Registry.

Saeed F, Arrigain S, Schold JD, Nally JV Jr, Navaneethan SD.

Nephron. 2019;141(2):98-104. doi: 10.1159/000494298. Epub 2018 Nov 21. Review.

PMID:
30463082
6.

Intra-Arterial versus Intravenous Contrast and Renal Injury in Chronic Kidney Disease: A Propensity-Matched Analysis.

Chaudhury P, Armanyous S, Harb SC, Ferreira Provenzano L, Ashour T, Jolly SE, Arrigain S, Konig V, Schold JD, Navaneethan SD, Nally JV Jr, Nakhoul GN.

Nephron. 2019;141(1):31-40. doi: 10.1159/000494047. Epub 2018 Oct 26.

PMID:
30368506
7.

Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation.

Airy M, Schold JD, Jolly SE, Arrigain S, Bansal N, Winkelmayer WC, Nally JV Jr, Navaneethan SD.

Am J Nephrol. 2018;48(1):36-45. doi: 10.1159/000491023. Epub 2018 Jul 26.

8.

Dramatic secular changes in prognosis for kidney transplant candidates in the United States.

Schold JD, Arrigain S, Flechner SM, Augustine JJ, Sedor JR, Wee A, Goldfarb DA, Poggio ED.

Am J Transplant. 2019 Feb;19(2):414-424. doi: 10.1111/ajt.15021. Epub 2018 Aug 14.

PMID:
30019832
9.

Significantly Lower Rates of Kidney Transplantation among Candidates Listed with the Veterans Administration: A National and Local Comparison.

Augustine JJ, Arrigain S, Balabhadrapatruni K, Desai N, Schold JD.

J Am Soc Nephrol. 2018 Oct;29(10):2574-2582. doi: 10.1681/ASN.2017111204. Epub 2018 Jul 13.

10.

High-density lipoprotein cholesterol and causes of death in chronic kidney disease.

Navaneethan SD, Schold JD, Walther CP, Arrigain S, Jolly SE, Virani SS, Winkelmayer WC, Nally JV Jr.

J Clin Lipidol. 2018 Jul - Aug;12(4):1061-1071.e7. doi: 10.1016/j.jacl.2018.03.085. Epub 2018 Mar 30.

11.

Impact of Uric Acid Levels on Kidney Disease Progression.

Rincon-Choles H, Jolly SE, Arrigain S, Konig V, Schold JD, Nakhoul G, Navaneethan SD, Nally JV Jr, Rothberg MB.

Am J Nephrol. 2017;46(4):315-322. doi: 10.1159/000481460. Epub 2017 Oct 13.

PMID:
29032376
12.

Pragmatic Randomized, Controlled Trial of Patient Navigators and Enhanced Personal Health Records in CKD.

Navaneethan SD, Jolly SE, Schold JD, Arrigain S, Nakhoul G, Konig V, Hyland J, Burrucker YK, Dann PD, Tucky BH, Sharp J, Nally JV.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1418-1427. doi: 10.2215/CJN.02100217. Epub 2017 Aug 4.

13.

Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease.

Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Blum MF, Winkelmayer WC, Nally JV Jr.

Kidney Int. 2017 Nov;92(5):1272-1281. doi: 10.1016/j.kint.2017.04.030. Epub 2017 Jul 24.

14.

Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD.

Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Winkelmayer WC, Nally JV Jr.

Am J Kidney Dis. 2017 Aug;70(2):191-198. doi: 10.1053/j.ajkd.2016.11.018. Epub 2017 Feb 10.

15.

Associations of dysnatremias with mortality in chronic kidney disease.

Huang H, Jolly SE, Airy M, Arrigain S, Schold JD, Nally JV, Navaneethan SD.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1204-1210. doi: 10.1093/ndt/gfw209.

16.

Obstructive and Restrictive Lung Function Measures and CKD: National Health and Nutrition Examination Survey (NHANES) 2007-2012.

Navaneethan SD, Mandayam S, Arrigain S, Rahman M, Winkelmayer WC, Schold JD.

Am J Kidney Dis. 2016 Sep;68(3):414-21. doi: 10.1053/j.ajkd.2016.03.415. Epub 2016 Apr 27.

17.

Mortality Outcomes of Patients with Chronic Kidney Disease and Chronic Obstructive Pulmonary Disease.

Navaneethan SD, Schold JD, Huang H, Nakhoul G, Jolly SE, Arrigain S, Dweik RA, Nally JV Jr.

Am J Nephrol. 2016;43(1):39-46. doi: 10.1159/000444422. Epub 2016 Feb 19.

18.

Body mass index and causes of death in chronic kidney disease.

Navaneethan SD, Schold JD, Arrigain S, Kirwan JP, Nally JV Jr.

Kidney Int. 2016 Mar;89(3):675-82. doi: 10.1016/j.kint.2015.12.002. Epub 2016 Jan 12.

19.

A Trial of Lifestyle Modification on Cardiopulmonary, Inflammatory, and Metabolic Effects among Obese with Chronic Kidney Disease.

Navaneethan SD, Fealy CE, Scelsi AC, Arrigain S, Malin SK, Kirwan JP.

Am J Nephrol. 2015;42(4):274-81. doi: 10.1159/000441155. Epub 2015 Oct 24.

20.

Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.

Nakhoul GN, Huang H, Arrigain S, Jolly SE, Schold JD, Nally JV Jr, Navaneethan SD.

Am J Nephrol. 2015;41(6):456-63. doi: 10.1159/000437151. Epub 2015 Jul 25.

21.

Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.

Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, Nally JV Jr, Navaneethan SD.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1119-27. doi: 10.2215/CJN.11121114. Epub 2015 Jun 25.

22.

Renal resistive index and mortality in chronic kidney disease.

Toledo C, Thomas G, Schold JD, Arrigain S, Gornik HL, Nally JV, Navaneethan SD.

Hypertension. 2015 Aug;66(2):382-8. doi: 10.1161/HYPERTENSIONAHA.115.05536. Epub 2015 Jun 15.

23.

Cause-Specific Deaths in Non-Dialysis-Dependent CKD.

Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr.

J Am Soc Nephrol. 2015 Oct;26(10):2512-20. doi: 10.1681/ASN.2014101034. Epub 2015 Jun 4.

24.

Development of a chronic kidney disease patient navigator program.

Jolly SE, Navaneethan SD, Schold JD, Arrigain S, Konig V, Burrucker YK, Hyland J, Dann P, Tucky BH, Sharp JW, Nally JV.

BMC Nephrol. 2015 May 3;16:69. doi: 10.1186/s12882-015-0060-2.

25.

Patency and Complications of Translumbar Dialysis Catheters.

Liu F, Bennett S, Arrigain S, Schold J, Heyka R, McLennan G, Navaneethan SD.

Semin Dial. 2015 Jul-Aug;28(4):E41-7. doi: 10.1111/sdi.12358. Epub 2015 Mar 20.

26.

Bariatric surgery, kidney function, insulin resistance, and adipokines in patients with decreased GFR: a cohort study.

Navaneethan SD, Malin SK, Arrigain S, Kashyap SR, Kirwan JP, Schauer PR.

Am J Kidney Dis. 2015 Feb;65(2):345-7. doi: 10.1053/j.ajkd.2014.09.018. Epub 2014 Nov 18. No abstract available.

27.

Adiposity measures, lean body mass, physical activity and mortality: NHANES 1999-2004.

Navaneethan SD, Kirwan JP, Arrigain S, Schold JD.

BMC Nephrol. 2014 Jul 8;15:108. doi: 10.1186/1471-2369-15-108.

28.

Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease.

Navaneethan SD, Sakhuja A, Arrigain S, Sharp J, Schold JD, Nally JV Jr.

Clin Nephrol. 2014 Jul;82(1):16-25. doi: 10.5414/CN108144.

PMID:
24887302
29.

Serum testosterone levels and mortality in men with CKD stages 3-4.

Khurana KK, Navaneethan SD, Arrigain S, Schold JD, Nally JV Jr, Shoskes DA.

Am J Kidney Dis. 2014 Sep;64(3):367-74. doi: 10.1053/j.ajkd.2014.03.010. Epub 2014 Apr 13.

30.

Chronic kidney disease in an electronic health record problem list: quality of care, ESRD, and mortality.

Jolly SE, Navaneethan SD, Schold JD, Arrigain S, Sharp JW, Jain AK, Schreiber MJ, Simon JF, Nally JV.

Am J Nephrol. 2014;39(4):288-96. doi: 10.1159/000360306. Epub 2014 Apr 1.

31.

Presence and outcomes of kidney disease in patients with pulmonary hypertension.

Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, Nally JV Jr, Schold JD, Rahman M, Dweik RA.

Clin J Am Soc Nephrol. 2014 May;9(5):855-63. doi: 10.2215/CJN.10191013. Epub 2014 Feb 27.

32.

Comparative effectiveness of early versus conventional timing of dialysis initiation in advanced CKD.

Crews DC, Scialla JJ, Boulware LE, Navaneethan SD, Nally JV Jr, Liu X, Arrigain S, Schold JD, Ephraim PL, Jolly SE, Sozio SM, Michels WM, Miskulin DC, Tangri N, Shafi T, Wu AW, Bandeen-Roche K; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

Am J Kidney Dis. 2014 May;63(5):806-15. doi: 10.1053/j.ajkd.2013.12.010. Epub 2014 Feb 6.

33.

Prediction of morbidity and mortality in patients with type 2 diabetes.

Wells BJ, Roth R, Nowacki AS, Arrigain S, Yu C, Rosenkrans WA Jr, Kattan MW.

PeerJ. 2013 Jun 11;1:e87. doi: 10.7717/peerj.87. Print 2013.

34.

Prognostic importance of serum alkaline phosphatase in CKD stages 3-4 in a clinical population.

Taliercio JJ, Schold JD, Simon JF, Arrigain S, Tang A, Saab G, Nally JV Jr, Navaneethan SD.

Am J Kidney Dis. 2013 Oct;62(4):703-10. doi: 10.1053/j.ajkd.2013.04.012. Epub 2013 Jun 12.

35.

Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with acute coronary syndromes.

Kumbhani DJ, Wells BJ, Lincoff AM, Jain A, Arrigain S, Yu C, Goormastic M, Ellis SG, Blackstone E, Kattan MW.

Am J Cardiovasc Dis. 2013;3(1):39-52. Epub 2013 Feb 17.

36.

Metabolic syndrome, ESRD, and death in CKD.

Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED, Beddhu S, Nally JV Jr.

Clin J Am Soc Nephrol. 2013 Jun;8(6):945-52. doi: 10.2215/CJN.09870912. Epub 2013 Feb 14.

37.

Obesity, anthropometric measures and chronic kidney disease complications.

Navaneethan SD, Kirwan JP, Arrigain S, Schreiber MJ, Sarnak MJ, Schold JD.

Am J Nephrol. 2012;36(3):219-27. Epub 2012 Aug 28.

38.

Characteristics of duplex sonographic parameters over time after successful carotid artery stenting.

Kim ES, Sun Z, Kapadia S, Bajzer C, Arrigain S, Gornik HL.

J Ultrasound Med. 2012 Aug;31(8):1169-74.

PMID:
22837280
39.

Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease.

Navaneethan SD, Schold JD, Arrigain S, Thomas G, Jolly SE, Poggio ED, Schreiber MJ Jr, Sarnak MJ, Nally JV Jr.

Nephrol Dial Transplant. 2012 Aug;27(8):3228-34. doi: 10.1093/ndt/gfs058. Epub 2012 May 2.

40.

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Diabetes Obes Metab. 2012 Sep;14(9):803-9. doi: 10.1111/j.1463-1326.2012.01604.x. Epub 2012 Apr 29.

PMID:
22486923
41.

Overweight, obesity and intentional weight loss in chronic kidney disease: NHANES 1999-2006.

Navaneethan SD, Kirwan JP, Arrigain S, Schreiber MJ, Sehgal AR, Schold JD.

Int J Obes (Lond). 2012 Dec;36(12):1585-90. doi: 10.1038/ijo.2012.7. Epub 2012 Jan 31.

42.

The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, Jain A, Atreja A, Zimmerman RS.

Diabet Med. 2012 Aug;29(8):1029-35. doi: 10.1111/j.1464-5491.2012.03577.x.

PMID:
22248043
43.

Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease.

Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Wehbe E, Raina R, Simon JF, Srinivas TR, Jain A, Schreiber MJ Jr, Nally JV Jr.

Clin J Am Soc Nephrol. 2011 Oct;6(10):2395-402. doi: 10.2215/CJN.03730411. Epub 2011 Sep 1.

44.

Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD.

Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ Jr, Simon JF, Srinivas TR, Nally JV Jr.

Am J Kidney Dis. 2011 Oct;58(4):536-43. doi: 10.1053/j.ajkd.2011.04.028. Epub 2011 Aug 4.

45.

Sunscreen use: Non-Hispanic Blacks compared with other racial and/or ethnic groups.

Summers P, Bena J, Arrigain S, Alexis AF, Cooper K, Bordeaux JS.

Arch Dermatol. 2011 Jul;147(7):863-4. doi: 10.1001/archdermatol.2011.172. No abstract available.

46.

Effect of follicular fluid oxidative stress parameters on intracytoplasmic sperm injection outcome.

Bedaiwy MA, Elnashar SA, Goldberg JM, Sharma R, Mascha EJ, Arrigain S, Agarwal A, Falcone T.

Gynecol Endocrinol. 2012 Jan;28(1):51-5. doi: 10.3109/09513590.2011.579652. Epub 2011 Jun 30.

PMID:
21714695
47.

Implications of the CKD-EPI GFR estimation equation in clinical practice.

Schold JD, Navaneethan SD, Jolly SE, Poggio ED, Arrigain S, Saupe W, Jain A, Sharp JW, Simon JF, Schreiber MJ Jr, Nally JV Jr.

Clin J Am Soc Nephrol. 2011 Mar;6(3):497-504. doi: 10.2215/CJN.04240510. Epub 2010 Nov 29.

48.

Development and validation of an electronic health record-based chronic kidney disease registry.

Navaneethan SD, Jolly SE, Schold JD, Arrigain S, Saupe W, Sharp J, Lyons J, Simon JF, Schreiber MJ Jr, Jain A, Nally JV Jr.

Clin J Am Soc Nephrol. 2011 Jan;6(1):40-9. doi: 10.2215/CJN.04230510. Epub 2010 Nov 4.

49.

The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Diabetes Care. 2010 Jun;33(6):1224-9. doi: 10.2337/dc10-0017. Epub 2010 Mar 9.

50.

Long-term impact of respiratory viral infection after pediatric lung transplantation.

Liu M, Mallory GB, Schecter MG, Worley S, Arrigain S, Robertson J, Elidemir O, Danziger-Isakov LA.

Pediatr Transplant. 2010 May;14(3):431-6. doi: 10.1111/j.1399-3046.2010.01296.x. Epub 2010 Mar 4.

Supplemental Content

Loading ...
Support Center